Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) has provided an update.
Sihuan Pharmaceutical Holdings Group announced that its subsidiary, Huisheng Biopharmaceutical, received approval from China’s National Medical Products Administration for its Dapagliflozin Tablets, a treatment for type 2 diabetes. This approval enhances the company’s product lineup in the diabetes sector and provides improved treatment options for patients, aligning with the growing market demand for SGLT-2 inhibitors, which are recognized for their efficacy in managing blood glucose and offering cardiovascular and renal benefits.
More about Sihuan Pharmaceutical Holdings Group
Sihuan Pharmaceutical Holdings Group, founded in 2001 and listed on the Hong Kong Stock Exchange in 2010, is a prominent player in the medical aesthetics and pharmaceutical industry. The company focuses on innovation with a strong R&D platform, a diverse product pipeline, and efficient production capabilities. Its subsidiary, Huisheng Biopharmaceutical, specializes in diabetes and related complications, offering a comprehensive range of products and integrated treatment solutions.
YTD Price Performance: 142.00%
Average Trading Volume: 200
Technical Sentiment Signal: Sell
Current Market Cap: $793.8M
Learn more about 0460 stock on TipRanks’ Stock Analysis page.